Journal of The Korean Ophthalmological Society (대한안과학회지)

The Korean Ophthalmological Society (대한안과학회)
권호 표지
DOI QR코드

DOI QR Code

Factors Affecting Compliance With 0.05% Cyclosporine Emulsion in Patients With Dry Eye Syndrome

건성안 환자에서 0.05% 싸이클로스포린 점안제의 순응도에 영향을 미치는 인자

  • Im, Seong-Kyu (Department of Ophthalmology, Chonnam National University Medical School and Hospital) ;
  • Yoon, Kyung-Chul (Department of Ophthalmology, Chonnam National University Medical School and Hospital)
  • 임성규 (전남대학교 의과대학 안과학교실) ;
  • 윤경철 (전남대학교 의과대학 안과학교실)
  • Received : 2009.07.27
  • Accepted : 2010.05.18
  • Published : 2010.07.15
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the factors affecting compliance with the use of 0.05% cyclosporine emulsion in patients with dry eye syndrome. Methods: A total of 148 patients using 0.05% cyclosporine emulsion for dry eye were divided into two groups (compliant vs. non-compliant). The compliant group included the patients who used 0.05% cyclosporine emulsion more than 50% of frequency as they had been prescribed. We analyzed factors affecting compliance, including age, gender, severity of symptoms, side effects, use of topical steroid, socioeconomic status, associated systemic disease, number of eyedrops, visit interval, and detailed instruction about 0.05% cyclosporine emulsion. Results: The compliant group included 124 patients (83.8%), and the non-compliant group included 24 patients (16.2%). Multivariate analysis showed that the factors associated with low compliance were severe symptoms, longer visit interval, side effects, lower socioeconomic status, and poor detailed instruction (P<0.05). In contrast, gender, associated systemic disease, and number of eyedrops did not affect the compliance for use of 0.05% cyclosporine emulsion. Conclusions: Special attention should be given to patients with the above risk factors to improve compliance with the use of 0.05% cyclosporine emulsion.

목적: 건성안 환자에서 0.05% 싸이클로스포린 점안제의 순응도에 영향을 미치는 인자에 대해 알아보고자 하였다. 대상과 방법: 건성안으로 0.05% 싸이클로스포린 점안제를 사용 중인 148명을 대상으로, 처방된 횟수대로 안약을 사용한 빈도가 50% 이상인 환자들을 순응도가 좋은 경우로 하여 두 군으로 분류하였다. 나이, 성별, 증상의 정도, 안약의 수, 사회경제적 상태, 부작용, 상세한 설명 유무 등을 분석하여, 이 중 순응도와 관련 있는 인자를 조사하였다. 결과: 순응도가 좋은 군은 124명(83.8%), 순응도가 좋지 않은 군은 24명(16.2%)이었다. 다변량 로지스틱 회귀분석을 시행한 결과 증상이 심한 경우, 외래진료 간격이 긴 경우, 부작용이 있는 경우, 사회경제적 상태가 낮은 경우, 자세한 설명을 듣지 못한 경우 등이 순응도를 낮추는 인자로 분석되었다(P<0.05). 나이, 성별, 사용한 안약의 수, 전신질환의 동반 유무 등의 인자들은 의미 없는 결과를 보였다. 결론: 건성안 환자에서 0.05% 싸이클로스포린 점안제 사용 시 상기 인자들을 충분히 고려하는 것이 치료 순응도를 높이는 데 도움이 될 것으로 생각된다.

Keywords

References

  1. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 2007;5:75-92. https://doi.org/10.1016/S1542-0124(12)70081-2
  2. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000;107:631-9. https://doi.org/10.1016/S0161-6420(99)00176-1
  3. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderateto- severe dry eye disease: a dose-ranging, randomized trial. Cyclosporine A Phase 2 Study Group. Ophthalmology 2000; 107:967-74. https://doi.org/10.1016/S0161-6420(00)00035-X
  4. Perry HD, Donnenfeld ED. Topical 0.05% cyclosporine A in the treatment of dry eye. Expert Opin Phamacother 2004;5:2099-107. https://doi.org/10.1517/14656566.5.10.2099
  5. Trattler W, Katsev D, Kerney D. Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys. Clin Ther 2006;28:1848-56.
  6. Chiang TH, Walt JG, McMahon JP Jr. Real-world utilization patterns of cyclosporine ophthalmic emulsion 0.05% within managed care. Can J Clin Pharmacol 2007;14:240-5.
  7. Lam H, Bleiden L, De Paiva CS, et al. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol 2009;147:198-205. https://doi.org/10.1016/j.ajo.2008.08.032
  8. Chen JJ, Rao K, Pflugfelder SC. Corneal epithelial opacity in dysfunctional tear syndrome. Am J Ophthalmol 2009;148:376-82. https://doi.org/10.1016/j.ajo.2009.04.023
  9. Krishnaiah S, Vilas K, Shamanna BR, et al. Smoking and its association with cataract: results of the Andhra Pradesh eye study from India. Invest Ophthalmol Vis Sci 2005;46:58-65. https://doi.org/10.1167/iovs.04-0089
  10. Nussenblatt RB, Palestine AG. Cyclosporin: immunology, pharmacology and therapeutic use. Surv Ophthalmol 1986;31:159-69. https://doi.org/10.1016/0039-6257(86)90035-4
  11. Hoffmann F, Wiederholt M. Local treatment of corneal transplants in the human with cyclosporin A. Klin Monatsbl Augenheikd 1985;187:92-6. https://doi.org/10.1055/s-2008-1050995
  12. Kilic A, Gürler B. Topical 2% cyclosporine A in preservative free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol 2006;41:693-8. https://doi.org/10.3129/I06-061
  13. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006;25:171-5. https://doi.org/10.1097/01.ico.0000176611.88579.0a
  14. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 2002;120: 330-7. https://doi.org/10.1001/archopht.120.3.330
  15. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderateto-severe dry eye disease: a dose-ranging, randomized trial. Cyclosporine A Phase 2 Study Group. Ophthalmology 2000;107: 967-74. https://doi.org/10.1016/S0161-6420(00)00035-X
  16. Brignole F, Pisella PJ, De Saint Jean M, et al. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporine A. Invest Ophthalmol Vis Sci 2001; 42:90-5.
  17. Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea 2000;19:492-6. https://doi.org/10.1097/00003226-200007000-00018
  18. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000;118:1489-96. https://doi.org/10.1001/archopht.118.11.1489
  19. Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea 1993;12:413-9. https://doi.org/10.1097/00003226-199309000-00008
  20. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Am J Ophthalmol 2005;112:1790-4.
  21. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995;26:233-6.
  22. MacKean JM, Elkington AR. Compliance with treatment of patients with chronic open angle glaucoma. Br J Ophthalmol 1983; 67:46-9. https://doi.org/10.1136/bjo.67.1.46
  23. Konstas AG, Maskaleris G, Gratsonidis S, Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye 2000;14:752-6. https://doi.org/10.1038/eye.2000.197
  24. Ahn DH, Lee YG, Hong YJ. Factors affecting compliance with prescribed eyedrops for glaucoma. J Korean Ophthalmol Soc 1998;39:2145-51.

Cited by

  1. 한의학 학술지에 게재된 안구건조증에 대한 논문 고찰 vol.31, pp.2, 2017, https://doi.org/10.15188/kjopp.2017.04.31.2.94
  2. 건성안 증후군 환자에서 인목탕의 유효성 평가를 위한 후향적 관찰연구 vol.27, pp.4, 2019, https://doi.org/10.14374/hfs.2019.27.4.285
  3. RAW 264.7 cell의 염증반응에 대한 산열음자(散熱飮子)의 항염증 효과 vol.34, pp.1, 2020, https://doi.org/10.15188/kjopp.2020.02.34.1.7